secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0001213900-24-072251
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA shareholders approve merger with Oruka; 1-for-12 reverse split set for Sept 3 trading under ORKA
--------------------------------------------------------------------------------

- Shareholders approved all 9 proposals at Aug 22 special meeting, including merger, share increase to 545M, and reverse split.
- Board set reverse stock split ratio at 1-for-12; outstanding shares to drop from ~14.5M to ~1.21M.
- Post-merger combined company expected to have ~29.5M common shares, plus ~5.4M pre-funded warrants and ~11.4M Series B convertible shares.
- Merger expected to close Aug 29; shares to trade as Oruka Therapeutics under ticker 'ORKA' on Nasdaq Global Market starting Sept 3.
- New CUSIP 687604108 and ISIN US6876041087 assigned after reverse split; cash in lieu of fractional shares at Sept 3 closing price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390024072251/0001213900-24-072251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390024072251/ea021219701-8k_arcabio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-072251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer